Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

NeoStem Acquires Asia Rights to Stem Cell Treatment

publication date: May 11, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NeoStem, Inc. in-licensed the Asia rights for Regenrexx™, a process that uses a patient’s own mesenchymal stem cells to regenerate joints and bones as an alternative to surgery. Regenerexx was the second mesenchymal stem cell in-licensing deal for NeoStem in as many weeks. Last week, NeoStem announced it had acquired worldwide rights for Primcel, a product that aids wound healing. More details...

Stock Symbol: (NYSE Amex: NBS)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners